Title: Prescribing of different antibiotics, rates of sepsis-related mortality and bacteremia in the US and England, and the utility of antibiotic replacement vs. reduction in prescribing

Short title: Antibiotic prescribing and rates of bacteremia and sepsis-related mortality

Author: Edward Goldstein

Affiliation: Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA 02115 USA. Email: egoldste@hsph.harvard.edu

Author contributions: Designed study, performed inference, wrote paper (EG).

Abstract

Background: Antibiotic use contributes to the rates of bacteremia, sepsis and associated mortality, particularly through lack of clearance of resistant infections following antibiotic treatment. At the same time, there is limited information on the effects of prescribing of some antibiotics vs. others on the rates of outcomes related to severe bacterial infections.

Methods: We looked at associations (univariate, as well as multivariable for the US data) between the proportions (state-specific in the US, Clinical Commissioning Group (CCG)-specific in England) of different antibiotic types/classes among all prescribed antibiotics in the outpatient setting (oral antibiotics in the US), and rates of outcomes (mortality with sepsis, ICD-10 codes A40-41 present on the death certificate in different age groups of US adults, and *E. coli* and MSSA bacteremia in England) per unit of antibiotic prescribing (defined as the rate of outcome divided by the rate of prescribing of all antibiotics).

Results: In the US, prescribing of penicillins was associated with rates of mortality with sepsis for persons aged 75-84y and 85+y between 2014-2015, while multivariable analyses also shown an association between the percent of individuals aged 50-64y lacking health insurance, as well as the percent of individuals aged 65-84y who are African-American and rates of mortality with sepsis. In England, prescribing of penicillins other than amoxicillin/co-amoxiclav was associated with rates of both MSSA and *E. coli* bacteremia for the period between financial years 2014/15 through 2017/18.

Conclusions: Our results suggest that prescribing of penicillins is associated with rates of *E. coli* and MSSA bacteremia in England, and rates of mortality with sepsis in older US adults, which

agrees with our earlier findings. Those results, as well as the related epidemiological data suggest that replacement of certain antibiotics, particularly penicillins should be considered for reducing the rates of outcomes related to severe bacterial infections.

Introduction

Rates of hospitalization with septicemia and sepsis in the diagnosis, associated mortality, as well as monetary costs of those hospitalizations have been rising rapidly during the past decades in the US [1-4]. A recent estimate from the US CDC suggests that about 270,000 Americans die annually as a result of sepsis [5]. Moreover, that estimate is expected to increase significantly if longer-term, e.g. 90-day mortality following sepsis diagnosis is accounted for [6]. In England, while rates of certain severe infections and related mortality, such as *Clostridium difficile* infections and MRSA bacteremia have declined during recent years [7,8], rates of *E. coli* and MSSA bacteremia and associated mortality were increasing [7-9].

Bacteremia outcomes in England are laboratory confirmed and there is less uncertainty about the interpretation of the recorded trends for those outcomes compared to trends for septicemia/sepsis hospitalization rates in the US. Part of the reason behind the rapid growth in the rates of hospitalization with septicemia/sepsis in the diagnosis in the US is changes in diagnostic practices, including the implementation of sepsis screening protocols [10,11]. However, changes in diagnostic practices in the US cannot fully explain the rise in the rates of hospitalization with septicemia/sepsis in the diagnosis, particularly prior to 2010 [12]. Indeed, trends in the rates of hospitalizations with any diagnosis of sepsis in the US between 2003-2009 closely resemble the trends in the rates of hospitalizations that involved infection and the use of

76 mechanical ventilation (Figure 1 in [12]). Moreover, rates of hospitalization with severe sepsis in
 77 the diagnosis were growing robustly between 2008-2012, with the percent of hospitalizations
 78 with severe sepsis that involved multiple organ failure also rising during that period [13],
 79 suggesting genuine growth in the volume of hospitalization involving severe sepsis.
 80

81 Antibiotic use and resistance can contribute to the rates of bacteremia/sepsis hospitalization and
 82 mortality through several mechanisms, particularly lack of clearance of resistant
 83 infections/colonization following antibiotic treatment, with some of those infections
 84 subsequently devolving into bacteremia/sepsis, and lethal outcomes [14-19]. Some of the more
 85 direct evidence for the relation between antibiotic resistance and subsequent hospitalization with
 86 severe infections, including bacteremia/sepsis is described in [19,18]; evidence about the relation
 87 between antibiotic resistance for hospitalized patients with sepsis and mortality, particularly in
 88 the US is presented in [16,17]. Those relations suggest that replacement of certain antibiotics by
 89 those antibiotics to which prevalence of resistance is lower is expected to help bring down the
 90 rates of severe outcomes associated with bacterial infections. For example, prevalence of co-
 91 amoxiclav resistance in bacteremia outcomes in England, particularly *E. coli* bacteremia is very
 92 high [20] (e.g. more than twice as high as prevalence of co-amoxiclav resistance in *E. coli*-related
 93 urinary tract infections [21]), and use of co-amoxiclav [22], both in the hospital and the primary
 94 care settings, and possibly the use of related penicillins may contribute to the incidence of co-
 95 amoxiclav resistant *E. coli* infections/colonization and associated bacteremia outcomes. We note
 96 that guidelines for replacement of certain antibiotics by certain others are relatively less common
 97 compared to the recommendation for overall reduction in antibiotic use issued by public health
 98 entities in different countries, e.g. [23]. However, reduction in antibiotic prescribing (rather than
 99 antibiotic replacement) is less likely to bring down the rates of bacteremia/sepsis in the short
 100 term as lack of treatment is generally worse than no treatment in relation to bacteremia/sepsis

101 outcomes. For example, rates of bacteremia kept growing rapidly in England [21] while the rates
 102 of antibiotic consumption in the UK dropped by 7.3% from 2014 to 2017 [23]. Moreover,
 103 reduction in prescribing, even a relatively modest one, may potentially contribute to increases in
 104 the volume of certain outcomes such as pneumonia [24,25]. At the same time, reduction in
 105 prescribing may help bring down the rates of severe bacterial infections in the longer term
 106 through decrease in antibiotic resistance (e.g. [9]) as antibiotic use is an important driver of the
 107 prevalence of antibiotic resistance [26-29,9]. Moreover, antibiotic use may contribute to the
 108 prevalence of resistance not only to the drug class used, but to other drugs as well as resistance to
 109 different drug classes tends to cluster in bacterial populations, leading to the phenomenon of co-
 110 selection [30,31]. For example, fluoroquinolone use was found to be associated with methicillin-
 111 resistant *S. aureus* (MRSA) infections [32-34], while amoxicillin use was found to be associated
 112 with trimethoprim resistance in Enterobacteriaceae in England [26], with trimethoprim
 113 resistance in urinary tract infections (UTIs) being positively associated with bacteremia outcomes
 114 [27].

115
 116 There is geographic variability in overall antibiotic prescribing rates within different countries
 117 including the US and England, with that variability being associated with variability in the
 118 prevalence of underlying health conditions and certain demographic factors [35,36], as well as
 119 variability in the rates of severe outcomes associated with bacterial infections [14] – see also
 120 Tables 1 and 5 in this paper. However, less is known about the effect of using some antibiotics vs.
 121 others in the treatment of various syndromes on the rates of bacteremia, septicemia/sepsis, and
 122 associated mortality. Our earlier work [14] studied the relation between the use of different
 123 antibiotics and rates of septicemia hospitalization in US adults. In this paper, we examine how the
 124 proportions of overall antibiotic prescribing that are for different antibiotic types/classes are
 125 related to the rates of *E. coli* and MSSA bacteremia in England, and the rates mortality with sepsis

in different age groups of US adults. Those analyses are based on state-level US CDC data on outpatient antibiotic prescribing and mortality between 2014-2015 in [37,38], and on the Clinical Commissioning Groups (CCG)-level English data (from Oxford U/PHE) on GP antibiotic prescribing and bacteremia [39,40]. Additionally, we use a multivariable framework to relate the proportions of overall outpatient antibiotic prescribing that are for fluoroquinolones, penicillins, cephalosporins and macrolides to rates of mortality with sepsis in different age groups of US adults, adjusting for additional covariates and random effects. We hope that such ecological analyses would lead to further work on the effect of antibiotic prescribing, including replacement of some antibiotics by others and reduction in antibiotic prescribing (as well as the comparison between the effect of antibiotic replacement vs. reduction in prescribing – see Discussion) on the rates of bacteremia, sepsis and associated mortality.

Materials and Methods

Data: All the data used in this study are publicly available and accessible through refs. [37-40,42-45] as described below.

1. US. Data on annual state-specific mortality with sepsis (ICD-10 codes A40-A41.xx representing either the underlying or a contributing cause of death) between 2014-2015 for different age groups of adults (18-49y, 50-64y, 65-74y, 75-84y, 85+y) were extracted from the US CDC Wonder database [38]. For each age group, those data are available for the 50 US states and the District of Columbia (sample size of 51). We note that for most of those deaths, sepsis is listed as a contributing rather than the underlying cause of death on the death certificate [41]. Data on the annual state-specific per capita rates of outpatient prescribing for four classes of oral antibiotics:

151 fluoroquinolones, penicillins, macrolides, and cephalosporins, as well as overall antibiotic
 152 prescribing in different states in 2014 and 2015 were obtained from the US CDC Antibiotic
 153 Patient Safety Atlas database [37]. Annual state-specific population estimates in each age group of
 154 adults (overall, as well as the number of African-Americans) were obtained as the yearly July 1
 155 population estimates in [42]. Data on median household income for US states between 2014-2015
 156 were extracted from [43]. Data on average daily temperature for US states were obtained from
 157 [44]. Data on the percent of state residents in different age groups who lacked health insurance
 158 were extracted from the US Census Bureau database [45].

159

160 2. *England*. We've considered the following nine antibiotic types/classes:

161

- 162 1. Amoxicillin (British National Formulary (BNF) code 0501013B0)
- 163 2. Co-amoxiclav (Amoxicillin/Clavulanic acid) (BNF code 0501013K0)
- 164 3. Penicillins (BNF section 5.1.1) excluding amoxicillin/co-amoxiclav
- 165 4. Tetracyclines (BNF section 5.1.3)
- 166 5. Macrolides (BNF section 5.1.5)
- 167 6. Cephalosporins + other beta-lactams (BNF section 5.1.2)
- 168 7. Fluoroquinolones (BNF section 5.1.12)
- 169 8. Trimethoprim (BNF code 0501080W0)
- 170 9. Urinary Tract Infection antibiotics (BNF 5.1.13 --
 171 nitrofurantoin/fosfomycin/methenamine)

172

173 For each antibiotic type/class above, we've extracted data for the different Clinical
 174 Commissioning Groups (CCGs) on the proportion of that antibiotic type/class among all General
 175 Practitioner (GP) antibiotic prescriptions (BNF classes 5.1.1 through 5.1.13) in the given CCG for

176 each of the financial years (April through March) 2014/15 through 2017/18 [39]. We've also
 177 extracted CCG/year specific data on the prescribing of all antibiotics per 1,000 residents, as well
 178 as per 1,000 STAR-PU's [39,46]. In addition to prescribing data, we've extracted CCG/year-specific
 179 data on the (population-adjusted) rates of *E. coli* and MSSA bacteremia for each of the financial
 180 years 2014/15 through 2017/18 [40]. We note that mergers of certain CCGs took place during the
 181 study period, and not all CCGs reported all the data needed for our analyses. For the 197 CCGs
 182 that reported data in [41], we have included data on 189 CCGs that reported both annual data on
 183 *E. coli* and MSSA bacteremia, as well as data on prescribing of the nine antibiotic types/classes
 184 above for each of the financial years 2014/15 through 2017/18.

185

186 ***Univariate Correlations (US and England)***

187

188 The contribution of prescribing of a given antibiotic type/class to the rates of severe outcomes
 189 associated with bacterial infections (e.g. bacteremia, or mortality with sepsis) is expected to be
 190 proportional to the rate of prescribing of that antibiotic type/class. One of the factors that
 191 modulates the relationship between the rates of antibiotic prescribing and rate of severe
 192 outcomes is the rate of infection that affects both prescribing and severe outcomes.
 193 Correspondingly, associations between rates of antibiotic prescribing and rates of severe
 194 outcomes associated with bacterial infections are often positive (e.g. Tables 1 and 5 in this paper).
 195 Moreover, the use of certain antibiotics may have a stronger association with severe outcomes
 196 than the use of certain other antibiotics, e.g. due to differences in the prevalence of resistance to
 197 different antibiotics. If a unit of prescribing of a given antibiotic type/class has a stronger
 198 association with the rate of a given severe outcome compared to prescribing of an average
 199 antibiotic dose (e.g. as a result of high prevalence of resistance to a given antibiotic), the
 200 association between the *proportion* of given antibiotic type/class among all antibiotics prescribed

201 and the rate of a given severe outcome *per unit of antibiotic prescribing* (defined as the rate of
 202 severe outcomes divided by the rate of prescribing of all antibiotics) is expected to be positive.
 203 We note that such disproportionate effects of prescribing of a unit of a given antibiotic can be the
 204 result not only of treatment of infections leading to a given outcome by a given antibiotic, but also
 205 of the contribution of the use of a given antibiotic to the rates of infection/colonization with
 206 different bacteria, and the prevalence of resistance to other antimicrobials (see Introduction).
 207 Additionally, correlations between proportions of a given antibiotic type/class among all oral
 208 antibiotics prescribed and the rates of severe outcomes per unit of antibiotic prescribing can also
 209 be affected by patterns of antibiotic prescribing in different locations, including changes in those
 210 patterns resulting from increases in resistance, introduction of new prescribing guidelines, etc.
 211 Correspondingly, we studied correlations between the proportions (state-specific in the US, CCG-
 212 specific in England) of a given antibiotic type/class among all prescribed antibiotics in the
 213 outpatient setting, and rates of outcome (mortality with sepsis in different age groups of adults in
 214 the US, and *E. coli*, as well as MSSA bacteremia in England) per unit of antibiotic prescribing, with
 215 the caveats above regarding the causal relations underlying those correlations. The US analysis is
 216 done for the 2014-2015 period; given the ongoing changes in antibiotic prescribing patterns in
 217 England [23], correlations for the English data were computed for each financial year between
 218 2014/15 through 2017/18.

219

220 ***Multivariable model (US data)***

221

222 In this section, we apply a mixed-effect multivariable model to adjust for various factors that
 223 affect the relation between prescribing of different antibiotics and rates of severe outcomes
 224 (including mortality) associated with bacterial infections. The relevant data for a multivariable
 225 model were only available for the US. For each age group of adults, (18-49y, 50-64y, 65-74y, 75-

84y, 85+y), we applied mixed effect models to relate the average annual state-specific outpatient prescribing rates (per 1,000 state residents) for oral fluoroquinolones, penicillins, macrolides, and cephalosporins between 2014-2015 to the average annual state-specific rates of sepsis mortality per 100,000 individuals in a given age group between 2014-2015 (dependent variable). Besides the antibiotic prescribing rates, the other covariates were the state-specific median household income, percentages of state residents in a given age group who were African American, those who lacked health insurance (in the non-elderly age groups, as health insurance, particularly Medicare coverage levels in the elderly are very high), as well as the state-specific average annual temperature. We note that sepsis mortality rates in African Americans are elevated [47]. We also note that temperature may influence bacterial growth rates and/or transmission mediated effects [48], which in turn may affect both the prevalence of antibiotic resistance [48], and the acquisition/severity of bacterial infections. To adjust for additional factors not accounted for by the covariates used in the model, we include random effects for the ten Health and Human Services (HHS) regions in the US. Specifically, for each state s , let $MR(s)$ be the average annual state-specific rate of mortality (per 100,000) with sepsis in the given age group between 2014-2015, $A_i(s)$ ($i = 1, \dots, 4$) be the average annual state-specific outpatient prescribing rates, per 1,000 state residents (of all ages), for the four studied classes of antibiotics between 2014-2015 (thus $A_1(s)$ denotes the rate of prescribing of oral fluoroquinolones, etc.); $I(s)$ be the median state-specific household income between 2014-2015; $T(s)$ be the state-specific average annual temperature (°F) between 2002-2011; $AA(s)$ be the age-specific percent of state residents between 2014-2015 who were African American; $LHI(s)$ be the average annual age-specific percent of state residents who lacked health insurance between 2014-2015 (for non-elderly age groups); $\alpha(s)$ be the random effect for the corresponding HHS region, and ε be the residual. Then

$$MR(s) = \beta_0 + \sum_{i=1}^4 \beta_i \cdot A_i(s) + \beta_5 \cdot I(s) + \beta_6 \cdot T(s) + \beta_7 \cdot AA(s) + \\ + \beta_8 \cdot LHI(s) + \alpha(s) + \varepsilon \quad (1)$$

We note that if we divide eq. 1 by the state-specific rates of overall outpatient prescribing of oral antibiotics, the resulting equation expresses (models) a linear relation between proportions of the overall antibiotic prescribing that are for fluoroquinolones, penicillins, macrolides, and cephalosporins, and other covariates and sepsis mortality rates per unit of antibiotic prescribing. Thus, eq. 1 can be thought of as a multivariable model for the relation between proportions of overall oral antibiotic prescribing that are for given antibiotic types/classes and rates of outcomes associated with bacterial infections per unit of oral antibiotic prescribing, with a univariate model for those relations studied in the previous subsection of the Methods.

Results

1. US

Table 1 shows, for each age group of adults, the mean (standard deviation) for the state-specific average annual rates of mortality with sepsis per 100,000 individuals in that age group between 2014-2015, as well as the linear correlation between those rates and state-specific rates of outpatient prescribing of all oral antibiotics. The latter correlations are high, ranging from 0.59(0.37,0.74) for ages 85+y to 0.77(0.62,0.68) for ages 65-74y. Additionally, annual rates of mortality with sepsis increase rapidly with age, from the state-specific mean of 8.31/100,000 for persons aged 18-49y to a mean of 750/100,000 for persons aged 85+y.

	Mean (standard deviation)	Linear correlation with rate of prescribing of all oral antibiotics
Sepsis mortality rate, ages 18-49y	8.31 (2.98)	0.66(0.47,0.79)
Sepsis mortality rate, ages 50-64y	55.8 (17.3)	0.74(0.59,0.84)
Sepsis mortality rate, ages 65-74y	143.4 (36.5)	0.77(0.62,0.68)
Sepsis mortality rate, ages 75-84y	330.8 (75.6)	0.67(0.48,0.80)
Sepsis mortality rate, ages 85+y	750 (161.9)	0.59(0.37,0.74)

273

274 **Table 1:** State-specific rates of mortality with sepsis (ICD-10 codes A40-41.xx present as either
275 underlying or contributing causes on a death certificate) per 100,000 individuals in different age
276 groups between 2014-2015 (mean + standard deviation), and the linear correlation between
277 those rates and state-specific rates of outpatient prescribing of all oral antibiotics.

278

279 Table 2 shows correlations (both linear and Spearman) for each pair of antibiotic classes between
280 the state-specific percentages of all outpatient oral antibiotic prescriptions that were for each
281 antibiotic class between 2014-2015, as well as the mean (standard deviation) for the state-
282 specific percentages of all outpatient oral antibiotic prescriptions that were for each antibiotic
283 class between 2014-2015. There is a strong negative correlation between the percentages of
284 outpatient prescribing of oral antibiotics that are for fluoroquinolones and that are for penicillins;
285 the Spearman correlation between percentages of antibiotic prescribing that are for penicillins

286 and that are for cephalosporins is also negative. Those negative correlations suggest competition
 287 between certain antibiotics in outpatient prescribing for various syndromes. We also note that on
 288 average, 66.2% of all outpatient oral antibiotic prescriptions in different states were for the four
 289 studied classes of antibiotics. Additionally, proportions of different antibiotic classes among all
 290 oral antibiotics prescribed in the outpatient setting in the US are notably different from the
 291 corresponding proportions in England (compare Table 2 with Table 6). Those differences,
 292 particularly for fluoroquinolones and cephalosporins may be related to differences in the rates of
 293 severe bacterial infections, particularly *Clostridium difficile* (C. difficile) infections between the
 294 two countries [49], with reduction in fluoroquinolone and cephalosporin prescribing found to be
 295 associated with reduction in the incidence of C. difficile infection in both countries [50,51].
 296
 297

	Mean (standard deviation)	Linear (Pearson) correlation with proportions of other antibiotic classes		
		Proportion penicillins	Proportion cephalosporins	Proportion Macrolides
Proportion fluoroquinolones	11.81% (1.22%)	-0.563 (-0.73,-0.34)	-0.141 (-0.4,0.14)	0.123 (-0.16,0.39)
Proportion Penicillins	22.57% (1.64%)		-0.262 (-0.5,0.01)	-0.235 (-0.48,0.04)
Proportion cephalosporins	13.56% (1.75%)			-0.164 (-0.42,0.12)
Proportion macrolides	18.22% (1.21%)			

	Mean (standard deviation)	Spearman correlation with proportions of other antibiotic classes		
		Proportion penicillins	Proportion cephalosporins	Proportion Macrolides
Proportion fluoroquinolones	11.81% (1.22%)	-0.436 (0.0015)	-0.069 (0.63)	0.114 (0.42)
Proportion penicillins	22.57% (1.64%)		-0.306 (0.03)	-0.192 (0.18)
Proportion cephalosporins	13.56% (1.75%)			-0.197 (0.16)

298

299 **Table 2:** Correlations (both linear (Pearson, with 95% confidence intervals) and Spearman (with
300 p-values)) between state-specific proportions of prescriptions for each antibiotic class among all
301 outpatient oral antibiotic prescriptions in the state for different pairs of antibiotic classes, as well
302 as the mean (standard deviation) for the average annual state-specific percentages of all
303 antibiotic prescriptions that were for each antibiotic class between 2014-2015.

304

305 Table 3 shows correlations (both Spearman and linear), for each antibiotic class and age group,
306 between average annual state-specific proportions of a given antibiotic class among the overall
307 outpatient oral antibiotic prescriptions and average annual state-specific rates of mortality with
308 sepsis in a given age group per unit of prescribed antibiotics (Methods) between 2014-2015. The
309 Spearman correlations are positive for penicillins for persons aged 75-84y and over 85y, and for
310 fluoroquinolones for persons aged 50-64y; the Spearman correlations are negative for
311 cephalosporins for persons aged 75-84y and over 85y, and for penicillins for persons aged 18-
312 49y. Among those six significant Spearman correlations, all the corresponding linear correlations

313 are also significant save for penicillins and mortality with sepsis in persons aged 75-84y (see also
 314 Table 4).
 315
 316

		Proportion fluoroquinolones	Proportion penicillins	Proportion cephalosporins	Proportion macrolides
Age 18-49y	Spearman	0.219 (0.12)	-0.36 (0.01)	0.262 (0.064)	0.235 (0.097)
	Linear	0.142 (-0.14,0.4)	-0.349 (-0.57,-0.08)	0.168 (-0.11,0.42)	0.269 (-0.01,0.51)
Age 50-64y	Spearman	0.419 (0.002)	-0.233 (0.1)	-0.063 (0.66)	0.185 (0.19)
	Linear	0.35 (0.08,0.57)	-0.183 (-0.44,0.1)	-0.151 (-0.41,0.13)	0.205 (-0.07,0.46)
Age 65-74y	Spearman	0.274 (0.052)	0.003 (0.98)	-0.247 (0.08)	0.092 (0.52)
	Linear	0.258 (-0.02,0.5)	-0.011 (-0.29,0.27)	-0.306 (-0.54,-0.03)	0.109 (-0.17,0.37)
Age 75-84y	Spearman	0.081 (0.57)	0.292 (0.038)	-0.418 (0.002)	-0.004 (0.98)
	Linear	0.028 (-0.25,0.3)	0.229 (-0.05,0.47)	-0.411 (-0.62,-0.15)	0.028 (-0.25,0.3)

Age	Spearman	-0.023 (0.87)	0.416 (0.003)	-0.422 (0.002)	-0.048 (0.74)
85+y	Linear	-0.04 (-0.31,0.24)	0.354 (0.09,0.57)	-0.442 (-0.64,-0.19)	-0.024 (-0.3,0.25)

317

318 **Table 3:** Correlations (both Spearman (p-value) and linear (Pearson, 95% CI)) between average
319 annual state-specific percent of overall outpatient oral antibiotic prescribing that is for a given
320 antibiotic class and average annual state-specific rates of mortality with sepsis in a given age
321 group per unit of prescribed oral antibiotics (Methods) between 2014-2015.

322

323 Table 4 shows the results of the multivariable model given by eq. 1. Table 4 suggests positive
324 associations (with largest effect size in the corresponding age groups) between rates of
325 outpatient prescribing of oral penicillins and sepsis mortality rates in individuals aged 75-84y
326 and 85+y, and a negative association between rates of outpatient prescribing of oral penicillins
327 and sepsis mortality rates in individuals aged 18-49y, all of which agree with the univariate
328 results in Table 3. Table 4 also suggests a positive association between the rates of outpatient
329 prescribing of oral cephalosporins and sepsis mortality rates in individuals aged 18-49y (with the
330 corresponding association failing to reach statistical significance in the univariate model), as well
331 as positive associations between the percent of individuals aged 50-64y lacking health insurance,
332 as well as the percent of individuals aged 65-74y and 75-84y who were African-American and
333 rates of mortality with sepsis.

334

335

336

	Aged 18-49y	Aged 50-64y	Aged 65-74y	Aged 75-84y	Aged 85+y
Fluoroquinolones (prescription per 1000 residents/y)	0.01 (-0.04,0.07)	0.15 (-0.15,0.45)	0.26 (-0.4,0.92)	-0.16 (-1.77,1.45)	-0.61 (-4.52,3.3)
Penicillins (prescription per 1000 residents/y)	-0.03 (-0.07,0)	0.08 (-0.1,0.25)	0.11 (-0.28,0.5)	0.95 (0.02,1.88)	2.97 (0.72,5.22)
Cephalosporins (prescription per 1000 residents/y)	0.05 (0.02,0.09)	0.07 (-0.11,0.25)	0.13 (-0.28,0.55)	-0.06 (-1.04,0.93)	-0.76 (-3.09,1.58)
Macrolides (prescription per 1000 residents/y)	0.02 (-0.02,0.06)	0.06 (-0.15,0.26)	0.21 (-0.26,0.69)	0.45 (-0.69,1.58)	0.71 (-2.03,3.45)
Median household income (\$1000)	-0.06 (-0.13,0.01)	-0.17 (-0.55,0.2)	-0.09 (-0.9,0.73)	0.54 (-1.4,2.49)	1.95 (-2.7,6.59)
Average minimal daily temperature (°F)	-0.04 (-0.11,0.03)	0.16 (-0.19,0.51)	0.33 (-0.44,1.1)	0.6 (-1.26,2.46)	4.07 (-0.55,8.7)
Percent African Americans	0.03 (-0.05,0.11)	0.28 (-0.06,0.63)	1.25 (0.41,2.1)	2.68 (0.76,4.6)	3.02 (-1.63,7.66)
Percent lacking health insurance	0.05 (-0.1,0.2)	0.95 (0.01,1.89)	ND	ND	ND

337

338 **Table 4:** Regression coefficients for the different covariates in the model given by eq. 1 for

339 different age groups. The coefficients for the different antibiotic classes estimate the change in the

340 annual sepsis mortality rates (per 10,000 individuals in a given age group) when the annual rate
341 of outpatient prescribing of oral antibiotics in the corresponding class (per 1,000 residents)
342 increases by 1. ND=not done because persons aged >64 years old are eligible for Medicare.

343

344 **2. England**

345 Table 5 shows summary statistics (mean + standard error) for the annual rates of *E. coli* and
346 MSSA bacteremia for the different CCGs for the 2014/15 through the 2017/18 financial years, as
347 well as the correlation between those rates and the rates of GP antibiotic prescribing, both per
348 1,000 residents and per 1,000 STAR-PUUs [46]. Table 5 suggests an ongoing increase in the rates of
349 MSSA bacteremia [7], with the long-term growth in the rates of *E. coli* bacteremia [9,7,21,40]
350 stalling in 2017/18. Table also 5 shows that for each of the 4 years in the data, for both the *E. coli*
351 and MSSA bacteremia rates, estimates of the correlation between those rates and antibiotic
352 prescribing per 1,000 residents are higher than the estimates of the correlation between those
353 rates and antibiotic prescribing per 1,000 STAR-Pus, suggesting that rates of severe bacterial
354 infections are reflected better by the actuality of antibiotic prescribing in England rather than by
355 the recommendations set by the STAR-PU system.

356

Outcome		2015/16	2016/17	2017/18	2017/18
<i>E. coli</i> bacteremia	Annual rate	67.72 (16.2)	71.76 (16.4)	75.81 (16.2)	76.15 (16.1)
	Correlation with antibiotic prescribing per 1,000 residents	0.362 (0.23,0.48)	0.458 (0.34,0.56)	0.489 (0.37,0.59)	0.489 (0.37,0.59)
	Correlation with antibiotic prescribing per 1,000 STAR-PUUs	0.311 (0.18,0.43)	0.417 (0.29,0.53)	0.443 (0.32,0.55)	0.435 (0.31,0.54)

MSSA bacteremia	Annual rate	18.39 (5.3)	19.84 (6.0)	21.01 (5.8)	21.86 (5.9)
	Correlation with antibiotic prescribing per 1,000 residents	0.246 (0.11,0.38)	0.459 (0.34,0.56)	0.449 (0.33,0.56)	0.389 (0.26,0.5)
	Correlation with antibiotic prescribing per 1,000 STAR-PUs	0.202 (0.06,0.34)	0.444 (0.32,0.55)	0.424 (0.3,0.53)	0.388 (0.26,0.5)

357

358 **Table 5:** Annual rates of *E. coli* and MSSA bacteremia for the different CCGs (mean + standard
359 error) for the 2014/15 through the 2017/18 financial years; correlations between those
360 bacteremia rates and rates of overall GP antibiotic prescribing, both per 1,000 residents and per
361 1,000 STAR-PUs [46].

362

363 Table 6 shows the mean + standard error for the annual CCG-specific rates of GP prescribing of
364 different antibiotic types/classes per 1,000 residents, as well as for the annual CCG-specific
365 proportions of those antibiotic types/classes among all prescribed antibiotics for the 2014/15
366 through the 2017/18 financial years. Table 6 suggests substantial temporal reduction in the
367 rates/proportions of prescribing for trimethoprim, co-amoxiclav and cephalosporins/other beta
368 lactams, as well as reduction in the rates/proportions of amoxicillin, fluroquinolone and
369 macrolide prescribing. Prescribing of UTI antibiotics (BNF 5.1.13 --
370 nitrofurantoin/fosfomycin/methenamine) increased markedly (with a good amount of
371 replacement of trimethoprim by nitrofurantoin in the treatment of UTIs taking place during the
372 study period, [20]), with proportions of penicillins other than amoxicillin/co-amoxiclav and
373 tetracyclines among all prescribed antibiotics also increasing. Additionally, significant reduction
374 in trimethoprim prescribing took place in 2017/2018 compared to 2016/17, and the growth in
375 the rate of *E. coli* bacteremia had also stalled then (Tables 6 and 5).

376

	2014/15		2015/16		2016/17		2017/18	
	Percent of all abx	Rate per 1,000	Percent of all abx	Rate per 1,000	Percent of all abx	Rate per 1,000	Percent of all abx	Rate per 1,000
Amoxicillin	28.35% (3.8%)	187.6 (36.3)	26.8% (3.7%)	162.9 (32.5)	26.75% (3.5%)	161.1 (31.4)	26.04% (3.4%)	150 (29.7)
Co-amoxiclav	5.44% (2.2%)	35.4 (14.6)	4.8% (1.9%)	28.8 (11.4)	4.28% (1.5%)	25.4 (9.4)	4.16% (1.4%)	23.6 (8.4)
Penicillins except amoxicillin/co-amoxiclav	17.67% (1.5%)	116.7 (18.1)	18.41% (1.6%)	111.8 (17.9)	18.6% (1.7%)	111.8 (18.4)	19.18% (1.8%)	110.4 (18.9)
Tetracyclines	11.59% (2.9%)	77.5 (23.7)	12.24% (2.9%)	75.4 (23)	12.74% (3%)	77.9 (24.1)	13.12% (3%)	77 (24)
Macrolides	12.66% (1.6%)	83.9 (16.6)	12.3% (1.5%)	75.1 (15.3)	12.19% (1.5%)	73.7 (15.4)	11.94% (1.4%)	69.1 (14.8)
Cephalosporins + other beta-lactams	3.3% (1.4%)	21.9 (10.3)	2.96% (1.2%)	18.1 (8.1)	2.7% (1.1%)	16.4 (7.5)	2.6% (1.1%)	15.2 (7.2)
Fluoroquinolones	1.96% (0.6%)	12.8 (3.8)	1.9% (0.5%)	11.4 (3.3)	1.87% (0.5%)	11.1 (3.1)	1.89% (0.5%)	10.8 (3)
Trimethoprim	10.33% (1.7%)	68.9 (16.6)	10.48% (1.9%)	64.5 (17)	9.8% (2.1%)	59.9 (17.7)	7.3% (1.8%)	42.8 (14.3)
UTI antibiotics	5.77% (1.4%)	38 (9.7)	7.01% (1.7%)	42.3 (10.3)	8.05% (2%)	48.1 (12.1)	10.67% (2.1%)	61.1 (13.9)

377

Table 6: Annual CCG-specific proportions (percentages) of a given antibiotic type/class among all GP antibiotic prescriptions (mean + standard error), and annual CCG-specific rates of GP prescribing per 1,000 individuals (mean + standard error) for nine antibiotic types/classes (Methods) during the 2014/15 through the 2017/18 financial years in England.

Tables 7 and 8 show correlations (both linear and Spearman) between CCG-specific proportions of different antibiotic types/classes among all GP antibiotic prescriptions and rates of *E. coli* (Table 7) and MSSA (Table 8) bacteremia per unit of antibiotic prescribing (Methods) for the 2014/15 through 2017/18 financial years. For penicillins other than amoxicillin/co-amoxiclav, correlations with rates of MSSA bacteremia were positive for all years, and correlations with rates of *E. coli* bacteremia were positive for the 2014/15 through 2016/17 financial years. For macrolides and fluoroquinolones, the corresponding correlations were generally negative. Correlations with bacteremia rates increased with time for proportions of UTI antibiotics, cephalosporins, and, to a smaller extent, amoxicillin prescribing; the corresponding correlations declined for proportions of trimethoprim and co-amoxiclav prescribing, with all those relative changes presumably related more to changes in prescribing patterns rather than changes in the causal relation between the use of a unit of those antibiotics and bacteremia outcomes. In particular, Tables 7 and 8 suggest that relative reductions in trimethoprim and co-amoxiclav prescribing were greater in places with higher bacteremia rates compared to places with lower bacteremia rates. Finally, we note that positive correlations with bacteremia rates for proportions of prescribing for penicillins other than amoxicillin/co-amoxiclav, but not for proportions of co-amoxiclav or amoxicillin prescribing need not suggest that penicillins other than amoxicillin/co-amoxiclav have a stronger relative impact on bacteremia rates than co-amoxiclav or amoxicillin; those differences may also have to do with geographic/demographic variation in the choice of different antibiotics, particularly penicillins.

403

	2014/15		2015/16		2016/17		2017/18	
	Linear	Spearman	Linear	Spearman	Linear	Spearman	Linear	Spearman
Amoxicillin	-0.058 (-0.2,0.09)	-0.048 (0.5)	0.017 (-0.13,0.16)	0.036 (0.62)	0.01 (-0.13,0.16)	0.017 (0.82)	0.02 (-0.12,0.16)	-0.007 (0.93)
Co-amoxiclav	-0.056 (-0.2,0.09)	-0.056 (0.44)	-0.118 (-0.26,0.03)	-0.146 (0.044)	-0.14 (-0.28,0)	-0.169 (0.02)	-0.14 (-0.28,0)	-0.175 (0.016)
Penicillins except amoxicillin/ co-amoxiclav	0.256 (0.12,0.38)	0.201 (0.006)	0.204 (0.06,0.34)	0.167 (0.02)	0.15 (0,0.28)	0.117 (0.11)	0.09 (-0.05,0.23)	0.06 (0.41)
Tetracyclines	0.171 (0.03,0.31)	0.201 (0.006)	0.095 (-0.05,0.23)	0.115 (0.12)	0.09 (-0.06,0.23)	0.104 (0.15)	-0.03 (-0.17,0.11)	0.02 (0.78)
Macrolides	-0.208 (-0.34,-0.07)	-0.248 (0.0006)	-0.14 (-0.28,0)	-0.156 (0.03)	-0.13 (-0.27,0.01)	-0.153 (0.035)	-0.07 (-0.21,0.08)	-0.091 (0.22)
Cephalosporins + other beta-lactams	-0.029 (-0.17,0.11)	0.023 (0.75)	0.03 (-0.11,0.17)	0.115 (0.11)	0.02 (-0.12,0.16)	0.039 (0.59)	0.12 (-0.02,0.26)	0.15 (0.039)
Fluoroquinolones	-0.276 (-0.4,-0.14)	-0.306 (0.00002)	-0.207 (-0.34,-0.07)	-0.242 (0.0008)	-0.18 (-0.32,-0.04)	-0.203 (0.005)	-0.12 (-0.26,0.02)	-0.162 (0.026)
Trimethoprim	-0.089 (-0.23,0.05)	-0.076 (0.30)	-0.279 (-0.41,-0.14)	-0.26 (0.0003)	-0.28 (-0.41,-0.15)	-0.235 (0.001)	-0.26 (-0.39,-0.12)	-0.273 (0.0002)
UTI antibiotics	0.038 (-0.1,0.18)	-0.065 (0.38)	0.153 (0.01,0.29)	0.044 (0.55)	0.21 (0.07,0.34)	0.135 (0.063)	0.19 (0.05,0.33)	0.164 (0.024)

404

405 **Table 7:** Correlations (both linear, with 95% CI, and Spearman, with p-value) between annual
406 proportions of different antibiotic types/classes among all GP antibiotic prescriptions and annual
407 rates of *E. coli* bacteremia per unit of antibiotic prescribing (Methods) for the different CCGs in
408 England, 2014/15 through 2017/18 financial years.

409

	2014/15		2015/16		2016/17		2017/18	
	Linear	Spearman	Linear	Spearman	Linear	Spearman	Linear	Spearman
Amoxicillin	-0.071 (-0.21,0.07)	-0.121 (0.10)	-0.047 (-0.19,0.1)	-0.076 (0.30)	-0.04 (-0.18,0.1)	-0.081 (0.27)	0.03 (-0.11,0.17)	-0.009 (0.90)
Co-amoxiclav	-0.114 (-0.25,0.03)	-0.112 (0.13)	-0.177 (-0.31,-0.04)	-0.193 (0.008)	-0.26 (-0.39,-0.12)	-0.313 (0.00001)	-0.29 (-0.42,-0.16)	-0.282 (0.00009)
Penicillins except amoxicillin/ co-amoxiclav	0.259 (0.12,0.39)	0.261 (0.0003)	0.218 (0.08,0.35)	0.172 (0.018)	0.2 (0.06,0.33)	0.196 (0.007)	0.26 (0.12,0.39)	0.232 (0.001)
Tetracyclines	0.135 (-0.01,0.27)	0.157 (0.032)	0.223 (0.08,0.35)	0.253 (0.0005)	0.14 (0,0.28)	0.234 (0.001)	0 (-0.14,0.15)	0.057 (0.43)
Macrolides	-0.155 (-0.29,-0.01)	-0.183 (0.012)	-0.183 (-0.32,-0.04)	-0.217 (0.003)	-0.17 (-0.31,-0.03)	-0.206 (0.005)	-0.13 (-0.27,0.01)	-0.151 (0.038)
Cephalosporins + other beta-lactams	-0.044 (-0.19,0.1)	-0.01 (0.89)	-0.046 (-0.19,0.1)	-0.024 (0.74)	0 (-0.14,0.15)	0.028 (0.71)	0.04 (-0.1,0.18)	0.075 (0.31)
Fluoroquinolones	-0.1 (-0.24,0.04)	-0.084 (0.25)	-0.206 (-0.34,-0.07)	-0.232 (0.001)	-0.12 (-0.26,0.02)	-0.18 (0.01)	-0.12 (-0.26,0.03)	-0.148 (0.04)
Trimethoprim	0.005 (-0.14,0.15)	0.017 (0.82)	-0.166 (-0.3,-0.02)	-0.132 (0.07)	-0.16 (-0.3,-0.02)	-0.101 (0.17)	-0.21 (-0.34,-0.07)	-0.214 (0.003)
UTI antibiotics	0.001 (-0.14,0.14)	-0.029 (0.69)	0.09 (-0.05,0.23)	0.022 (0.77)	0.16 (0.02,0.3)	0.069 (0.35)	0.12 (-0.02,0.26)	0.111 (0.13)

410

411 **Table 8:** Correlations (both linear, with 95% CI, and Spearman, with p-value) between annual
412 proportions of different antibiotic types/classes among all GP antibiotic prescriptions and annual
413 rates of MSSA bacteremia per unit of antibiotic prescribing (Methods) for different CCGs in
414 England, 2014/15 through 2017/18 financial years.

415

416

Discussion

Rates of mortality related to septicemia/sepsis in the US, as well as rates of *E. coli* bacteremia and associated mortality in England are high [1-3,5,7,8,21,40], and antimicrobial use may affect those rates through a variety of mechanisms (Introduction). At the same time, our understanding of the effect of the use of certain antibiotics vs. others for various indications on the rates of bacteremia, septicemia/sepsis and associated mortality is still limited. Additionally, use of certain antibiotics may affect the rates of severe outcomes associated with syndromes for which a given antibiotic is rarely prescribed as use of antibiotics may affect prevalence of infection/colonization and resistance to different antibiotics in different bacterial pathogens that subsequently cause various syndromes (Introduction). In this paper, we relate the proportions of different antibiotic types/classes among the overall volume of outpatient antibiotic prescription in different US states and English Clinical Commissioning Groups (CCGs) [37,39] to rates of mortality with sepsis in different age groups of US adults [38] and rates of *E. coli* and MSSA bacteremia in England [40]. Our results suggest, among other things, that prescribing of penicillins is associated with rates of *E. coli* and MSSA bacteremia in England, and rates of mortality with sepsis in older US adults, with the latter finding supporting our earlier results on the association between the use of penicillins and rates of septicemia hospitalization in older US adults [14]. We also note the high prevalence of resistance to penicillins in both the Gram-negative and Gram-positive infections [52-54]. Additionally, multivariable analyses of the US data suggest a positive association between the percent of individuals lacking health insurance and rates of mortality with sepsis in persons aged 50-64y, as well as the percent of individuals who are African-American and rates of mortality with sepsis in persons aged 65-84y, supporting the fact that rates of mortality with sepsis in African Americans are elevated [47]. While our results lend support for the replacement of penicillins by other antibiotics with the aim of reducing the rates of bacteremia/sepsis and

associated mortality, more granular analyses, particularly individual-level studies relating prescribing of different antibiotics in the treatment of a given syndrome to subsequent outcomes are needed to inform guidelines for antibiotic, particularly penicillin replacement, as well as for reduction in antibiotic prescribing, as explained further in the next two paragraphs.

Our findings about the positive associations between the use of penicillins and mortality with sepsis in older US adults are in agreement with the fact that prevalence of resistance to penicillins, particularly in older adults, is high for a variety of infections with both Gram-negative and Gram-positive bacteria [52-54]. Negative associations between the proportion of cephalosporins among all antibiotic prescriptions and rates of sepsis mortality in older US adults (Table 3) may be related to the competition in prescribing with other antibiotic classes, particularly penicillins and fluoroquinolones for which prevalence of resistance in the key syndromes leading to sepsis is higher than prevalence of resistance to cephalosporins, e.g. [52,55]. We note that those negative associations do not reach statistical significance in the multivariable model (Table 4). Moreover, prevalence of cephalosporin resistance and the frequency of extended-spectrum beta-lactamase (ESBL) production, including in Gram-negative bacteria is growing [56], and replacement of other antibiotics by cephalosporins might potentially lead to negative effects in the long run. Finally, we found no associations between the proportion of macrolides among all antibiotic prescriptions in the US and rates of mortality with sepsis in adults, which agrees with our earlier findings regarding septicemia hospitalizations [14]. While macrolides are used relatively infrequently in the treatment of urinary tract and gastrointestinal infections, macrolides are commonly prescribed in the treatment of other sources of sepsis, particularly respiratory illness, both chronic [57] and acute, including pneumonia [58], with high prevalence of macrolide resistance in the corresponding infections [59].

467

468 In England, prevalence of resistance to trimethoprim in urinary tract infections (UTIs) is high
 469 [21], and trimethoprim use was found to be associated with UTI-related *E. coli* bacteremia [27].
 470 Major reductions in trimethoprim prescribing in England took place in the recent years,
 471 particularly in 2017/2018 ([20]; Table 6 in this paper); moreover, prescribing of trimethoprim
 472 appears to have declined disproportionately in places in England with higher rates of *E. coli* and
 473 MSSA bacteremia (Results). All those changes might have played a role in the fact that growth in
 474 the rates of *E. coli* bacteremia in England has stalled in 2017/2018 after many years of robust
 475 increases (Table 5; [9,21,7,40]). Prevalence of co-amoxiclav resistance in *E. coli* bacteremia in
 476 England exceeds 40% [20,21], more than twice as high as the prevalence of co-amoxiclav
 477 resistance in *E. coli*-related urinary tract infections [21], suggesting that the use of co-amoxiclav
 478 and possibly of related penicillins is likely in the causal pathway for bacteremia outcomes. GP
 479 prescribing of co-amoxiclav was reduced significantly during the recent years ([20]; Table 6 in
 480 this paper), disproportionately in places with higher rates of bacteremia (Results). At the same
 481 time, prevalence of co-amoxiclav resistance in *E. coli* bacteremia and rates of the corresponding
 482 bacteremia outcomes are affected not only by GP prescribing of co-amoxiclav but also by other
 483 factors including the use of co-amoxiclav in secondary care, which is widespread [20,21], and
 484 possibly the use of related penicillins, with penicillin prescribing in secondary care increasing
 485 during the recent years [20]. We also note that amoxicillin use is associated with trimethoprim
 486 resistance [26], which in turn affects the rates of *E. coli* bacteremia [27], while use of different
 487 penicillins may also affect prevalence of resistance to piperacillin/tazobactam in *E. coli*
 488 bacteremia, which is sizeable [20]. Additionally, penicillins are widely prescribed in England,
 489 accounting for about half of all antibiotic prescriptions in primary care (e.g. Table 6), and
 490 penicillin use/resistance to penicillins is therefor expected to affect prevalence of
 491 infection/colonization with different bacterial pathogens that subsequently lead to bacteremia

outcomes. While positive correlations between rates of bacteremia and rates of prescribing for penicillins other than amoxicillin/co-amoxiclav, but not for amoxicillin or co-amoxiclav were found in this paper, it is uncertain which penicillins (including co-amoxiclav and amoxicillin) have a greater relative impact on rates of bacteremia, with the results of the correlation analyses in this paper potentially affected by patterns of prescribing of different antibiotics related to different geographic locations, as well as demographic factors. Overall, our results support some replacement of penicillins in England by other antibiotics, presumably ones for which prevalence of antimicrobial resistance is lower, as well as reduction in penicillin prescribing with the aim of reducing bacteremia rates. Additionally, we have found that prescribing of metronidazole for skin infections (BNF 1310012K0) as a proportion of the overall GP antibiotic prescribing is correlated with the CCG-specific rates of both *E. coli* and MSSA bacteremia per unit of antibiotic prescribing for the four years in the data. This suggests the possibility that demographic/geographic differences result in differences in transmission of infections/colonization with bacterial pathogens such as *S. aureus* and *E. coli* (including transmission through skin infections), which in turn may affect the rates of severe bacterial infections, including bacteremia. Further work is needed to better understand those differences in transmission, including the feasibility of mitigation efforts aimed at preventing infections.

The epidemiological situation related to bacteremia/sepsis in England and the US brings about the question regarding the relative utility of antibiotic replacement vs. reduction in antibiotic prescribing for reducing the rates of bacteremia/sepsis and the associated mortality. A key mechanism relating antibiotic use to the rates of severe outcomes associated with bacterial infection is lack of clearance of resistant infections following antibiotic treatment, with some of those infections subsequently devolving into bacteremia/sepsis and lethal outcomes. While replacement of antibiotics (particularly penicillins) by those to which prevalence of resistance is

517 lower should decrease the scale of this phenomenon, reduction in antibiotic prescribing without
518 antibiotic replacement is not expected to bring down the rates of severe outcomes associated
519 with bacterial infections, at least in the short term, as no treatment should generally be worse
520 compared to antibiotic treatment with regard to sepsis-related outcomes. We note that several
521 years of decreases in outpatient antibiotic prescribing in England before 2017/18 [23] did not
522 seem to have an effect on the long term growth in the rates of both *E. coli* and MSSA bacteremia
523 (Tables 6 and 5; [21,9,40]); at the same time, major replacement of trimethoprim by
524 nitrofurantoin in 2017/18 (Table 6) following the issue of the corresponding guidelines for the
525 treatment of UTIs ([21], p. 6) was accompanied by the stalling in the growth of the rates of *E. coli*
526 bacteremia in England (Table 5 and [40]). Moreover, reduction in antibiotic prescribing has
527 potential detrimental effects such as an increase in the volume of pneumonia hospitalization
528 [24,25]. Reduction in antibiotic prescribing may contribute to decreases in the rates of severe
529 outcomes associated with bacterial infections in the longer term through decreases in antibiotic
530 resistance. While overall recommendations for reduction in antibiotic use are commonly issued
531 by public health entities in different countries, e.g. [23], recommendations for replacement of
532 certain antibiotics by certain others in the treatment of certain syndromes (like the
533 recommendation for the replacement of trimethoprim by nitrofurantoin in England) are generally
534 less common. Such recommendations related to penicillin use (e.g. in-hospital co-amoxiclav
535 prescribing in England) should have a notable effect on the rates of bacteremia/sepsis and
536 associated mortality, both in England and the US. Finally, we note that recently, US FDA has
537 recommended the restriction of fluoroquinolone use for certain conditions (such as
538 uncomplicated UTIs) due to potential adverse effects [60]. At the same time, no indications for
539 antibiotics serving as replacement of fluoroquinolones were suggested in the FDA guidelines [60].
540 Such indications are needed to optimize the effect of those guidelines on the rates of severe
541 outcomes associated with bacterial infections rather than possibly contribute to increases in the

542 rates of such outcomes (e.g. increases in the rates of septicemia/sepsis through increases in the
543 prescribing of penicillins).
544

545 Our paper has some limitations. Associations between proportions of different antibiotic
546 types/classes (particularly penicillins) and rates of severe outcomes associated with bacterial
547 infections may be affected not only by the relative contributions of the use of a unit of different
548 antibiotics to the rates of those severe outcomes but also by patterns of antibiotic prescribing in
549 different locations. We note that penicillins are prescribed for a wide variety of indications, both
550 in England and the US, affecting prevalence of infection/colonization with different bacterial
551 pathogens, and that there is high prevalence of resistance to penicillins in both the Gram-negative
552 and Gram-positive bacteria in the US (e.g. [52-54]), and high prevalence of co-amoxiclav
553 resistance in *E. coli* bacteremia in England [20], all of which supports our results about the
554 relation between prescribing of penicillins and rates of severe outcomes associated with bacterial
555 infections. The antibiotic-sepsis mortality associations that we found in the multivariable model
556 estimate causal effects only if the model is well-specified and all confounders are accounted for in
557 the analysis. To adjust for potential effects of unmeasured and residual confounding, we included
558 random effects for the ten US Health and Human Services regions, which led to an improvement
559 in the model fits. Moreover, results of the univariate and the multivariable analyses generally
560 agree on the direction of the effect of different antibiotics on the rates of mortality with sepsis in
561 the US (Tables 3 and 4). Further work involving more granular data, particularly individual-level
562 analysis relating prescribing of different antibiotics in the treatment of a given syndrome to
563 subsequent outcomes is needed to better ascertain the strength of the associations found in this
564 paper. No hospital antibiotic prescribing data were available for this study, and in-hospital
565 antibiotic prescribing is expected to have a significant impact on the rates of outcomes associated
566 with severe bacterial infections. For example, given the very high prevalence of co-amoxiclav

resistance in *E. coli* bacteremia and the high levels of co-amoxiclav prescribing in the secondary care setting in England [20,21], it is likely that co-amoxiclav prescribing in the secondary care has a significant effect on the incidence of *E. coli* bacteremia in England, both co-amoxiclav resistant and overall. Coding practices for sepsis on death certificates may vary by US state [61]. Additionally, data on outpatient antibiotic prescribing in the whole population [37] were related to age-specific rates of mortality with sepsis in the US [38], while in England, no age-specific prescribing or bacteremia data were available for this study. We expect that those sources of noise/incompatibility should generally reduce precision and bias the correlations towards null rather than create spurious associations.

We believe that despite those limitations, our results suggest that prescribing of certain antibiotics, particularly penicillins is associated with rates of *E. coli* and MSSA bacteremia in England and rates of mortality with sepsis in older US adults, with the latter result supporting our earlier findings about the association between the rates of prescribing of penicillins and rates of hospitalization with septicemia in older US adults [14]. Additionally, there is high prevalence of resistance to penicillins for a variety of bacterial infections both in the US and England [52-54,20,21]. While these findings support the potential utility of replacement of penicillins by other antibiotics with the goal of reducing the rates of bacteremia/sepsis and associated mortality, further studies, including individual-level analyses are needed to better understand the effect of replacement of certain antibiotics, particularly penicillins by other antibiotics in the treatment of different syndromes, well as the effect of reduction in antibiotic prescribing in the treatment of certain conditions on the rates of severe outcomes associated with bacterial infections.

Acknowledgment: We thank Koen Pouwels for helpful discussions.

592

593

594 **References**

595

596 [1] Elixhauser A, Friedman B, Stranges E. Septicemia in U.S. Hospitals, 2009: Statistical Brief #122.

597 HealthCare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality

598 (AHRQ), 2011. Accessed on Jan. 12, 2019. Available from: [https://www.hcup-](https://www.hcup-us.ahrq.gov/reports/statbriefs/sb122.pdf)

599 [us.ahrq.gov/reports/statbriefs/sb122.pdf](https://www.hcup-us.ahrq.gov/reports/statbriefs/sb122.pdf)

600

601 [2] McDermott KW, Elixhauser A, Sun R. Trends in Hospital Inpatient Stays in the United States,

602 2005–2014. Statistical Brief #225. HealthCare Cost and Utilization Project (HCUP), Agency for

603 Healthcare Research and Quality (AHRQ), 2017. Accessed on Jan. 12, 2019. Available from:

604 <https://www.hcup-us.ahrq.gov/reports/statbriefs/sb225-Inpatient-US-Stays-Trends.pdf>

605

606 [3] Iwashyna TJ, Cooke CR, Wunsch H, Kahn JM. Population burden of long-term survivorship

607 after severe sepsis in older Americans. J Am Geriatr Soc. 2012;60(6):1070-7.

608

609 [4] Torio CM, Moore BJ. National Inpatient Hospital Costs: The Most Expensive Conditions by

610 Payer, 2013: Statistical Brief #204. HealthCare Cost and Utilization Project (HCUP), Agency for

611 Healthcare Research and Quality (AHRQ), 2016. Accessed on Jan. 12, 2019. Available from:

612 [https://www.hcup-us.ahrq.gov/reports/statbriefs/sb204-Most-Expensive-Hospital-](https://www.hcup-us.ahrq.gov/reports/statbriefs/sb204-Most-Expensive-Hospital-Conditions.jsp)

613 [Conditions.jsp](https://www.hcup-us.ahrq.gov/reports/statbriefs/sb204-Most-Expensive-Hospital-Conditions.jsp)

614

615 [5] US CDC. Sepsis. Data & Reports. (2018). Accessed on Jan. 12, 2019. Available from:

616 <https://www.cdc.gov/sepsis/datareports/index.html>

617

618 [6] Iwashyna TJ, Cooke CR, Wunsch H, Kahn JM. Population burden of long-term survivorship
619 after severe sepsis in older Americans. J Am Geriatr Soc. 2012;60(6):1070-7.

620

621 [7] Public Health England. Mandatory MRSA, MSSA and *E. coli* bacteraemia and *C. difficile*
622 infection data 2015/16. Annual Epidemiological Commentary. 2016. Accessed on Jan. 12, 2019.
623 Available from:

624 [https://www.researchgate.net/profile/Simon_Thelwall/publication/305392637_Annual_Epidem](https://www.researchgate.net/profile/Simon_Thelwall/publication/305392637_Annual_Epidemiological_Commentary_Mandatory_MRSA_MSSA_and_E_coli_bacteraemia_and_C_difficile_infection_data_201516/links/578ccb6a08ae254b1de8610a/Annual-Epidemiological-Commentary-Mandatory-MRSA-MSSA-and-E-coli-bacteraemia-and-C-difficile-infection-data-2015-16.pdf)
625 [iological_Commentary_Mandatory_MRSA_MSSA_and_E_coli_bacteraemia_and_C_difficile_infection](https://www.researchgate.net/profile/Simon_Thelwall/publication/305392637_Annual_Epidemiological_Commentary_Mandatory_MRSA_MSSA_and_E_coli_bacteraemia_and_C_difficile_infection_data_201516/links/578ccb6a08ae254b1de8610a/Annual-Epidemiological-Commentary-Mandatory-MRSA-MSSA-and-E-coli-bacteraemia-and-C-difficile-infection-data-2015-16.pdf)
626 [_data_201516/links/578ccb6a08ae254b1de8610a/Annual-Epidemiological-Commentary-](https://www.researchgate.net/profile/Simon_Thelwall/publication/305392637_Annual_Epidemiological_Commentary_Mandatory_MRSA_MSSA_and_E_coli_bacteraemia_and_C_difficile_infection_data_201516/links/578ccb6a08ae254b1de8610a/Annual-Epidemiological-Commentary-Mandatory-MRSA-MSSA-and-E-coli-bacteraemia-and-C-difficile-infection-data-2015-16.pdf)
627 [Mandatory-MRSA-MSSA-and-E-coli-bacteraemia-and-C-difficile-infection-data-2015-16.pdf](https://www.researchgate.net/profile/Simon_Thelwall/publication/305392637_Annual_Epidemiological_Commentary_Mandatory_MRSA_MSSA_and_E_coli_bacteraemia_and_C_difficile_infection_data_201516/links/578ccb6a08ae254b1de8610a/Annual-Epidemiological-Commentary-Mandatory-MRSA-MSSA-and-E-coli-bacteraemia-and-C-difficile-infection-data-2015-16.pdf)

628

629 [8] Thirty-day all-cause fatality subsequent to MRSA, MSSA and *E. coli* bacteraemia and *C. difficile*
630 infection, 2017/18. Oct. 2018. Accessed on Jan. 12, 2019. Available from
631 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/765014/HCAI_fatality_report_201718_v2.pdf)
632 [/file/765014/HCAI_fatality_report_201718_v2.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/765014/HCAI_fatality_report_201718_v2.pdf)

633

634 [9] Livermore DM, Hope R, Reynolds R, Blackburn R, Johnson AP, Woodford N. Declining
635 cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae
636 from the UK: links to prescribing change? J Antimicrob Chemother . 2013;68:2667-2674.

637

638 [10] Rhee C, Murphy MV, Li L, Platt R, Klompas M. Comparison of Trends in Sepsis Incidence and
639 Coding Using Administrative Claims Versus Objective Clinical Data. Clin Infect Dis. 2015;60(1):88-
640 95

641

- 642 [11] Umscheid CA, Betesh J, VanZandbergen C, Hanish A, Tait G, Mikkelsen ME, et al.
643 Development, implementation, and impact of an automated early warning and response system
644 for sepsis. J Hosp Med. 2015;10(1):26-31
645
- 646 [12] Walkey AJ, Lagu T, Lindenauer PK. Trends in sepsis and infection sources in the United
647 States. A population-based study. Ann Am Thorac Soc. 2015;12(2):216-20
648
- 649 [13] Stoller J, Halpin L, Weis M, Aplin B, Qu W, Georgescu C, et al. Epidemiology of severe sepsis:
650 2008-2012. J Crit Care. 2016;31(1):58-62 .
651
- 652 [14] Goldstein E, Olesen SW, Karaca Z, Steiner CA, Viboud C, Lipsitch M. Levels of outpatient
653 prescribing for four major antibiotic classes and rates of septicemia hospitalization in different US
654 states. BioRxiv 2018. Accessed on Jan. 12, 2019. Available from:
655 <https://www.biorxiv.org/content/early/2018/12/13/404046>
656
- 657 [15] Goldstein E, MacFadden DR, Karaca Z, Steiner CA, Viboud C, Lipsitch M. Antimicrobial
658 resistance prevalence, rates of hospitalization with septicemia and rates of mortality with sepsis
659 in adults in different US states. Int J Antimicrob Agents. 2019; pii: S0924-8579(19)30056-1
660
- 661 [16] Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-
662 analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents
663 Chemother. 2010;54(11):4851-63
664
- 665 [17] Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH. Multi-drug resistance,
666 inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic
667 shock: a retrospective cohort study. Crit Care. 2014;18(6):596

668

669 [18] Lee YC, Hsiao CY, Hung MC, Hung SC, Wang HP, Huang YJ, et al. Bacteremic Urinary Tract
670 Infection Caused by Multidrug-Resistant Enterobacteriaceae Are Associated With Severe Sepsis at
671 Admission: Implication for Empirical Therapy. *Medicine (Baltimore)*. 2016;95(20):e3694

672

673 [19] Hawkey PM, Warren RE, Livermore DM, McNulty CAM, Enoch DA, Otter JA, et al. Treatment
674 of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society
675 for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint
676 Working Party. *J Antimicrob Chemother*. 2018;73(suppl_3):iii2-iii78

677

678 [20] Public Health England. English Surveillance Programme for Antimicrobial Utilisation and
679 Resistance (ESPAUR). Report 2018. Accessed on Jan. 12, 2019. Available from:
680 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/759975/ESPAUR_2018_report.pdf)
681 [/file/759975/ESPAUR_2018_report.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/759975/ESPAUR_2018_report.pdf)

682

683 [21] Public Health England. English Surveillance Programme for Antimicrobial Utilisation and
684 Resistance (ESPAUR). Report 2017. Accessed on Jan. 12, 2019. Available from:
685 https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/656611/ESP
686 [AUR_report_2017.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/656611/ESP)

687

688 [22] Vihta KD, Stoesser N, Llewelyn M, Quan TP, Davies T, Fawcett NJ, et al. Trends over time in
689 *Escherichia coli* bloodstream infections, urinary tract infections, and antibiotic susceptibilities in
690 Oxfordshire, UK, 1998–2016: a study of electronic health records. *Lancet Infect Dis*.
691 2018;18(10):1138-1149

692

- 693 [23] UK Government. Tackling antimicrobial resistance 2019 – 2024: The UK’s five - year national
694 action plan. (2019). Accessed on June 1, 2019. Available from:
695 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data
696 [/file/784894/UK_AMR_5_year_national_action_plan.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/784894/UK_AMR_5_year_national_action_plan.pdf)
697
- 698 [24] Gulliford MC, Moore MV, Little P, Hay AD, Fox R, Prevost AT, et al. Safety of reduced antibiotic
699 prescribing for self limiting respiratory tract infections in primary care: cohort study using
700 electronic health records. BMJ. 2016;354:i3410
701
- 702 [25] Price DB, Honeybourne D, Little P, Mayon-White RT, Read RC, Thomas M, et al. Community-
703 acquired pneumonia mortality: a potential link to antibiotic prescribing trends in general
704 practice. Respir Med. 2004;98(1):17-24
705
- 706 [26] Pouwels KB, Freeman R, Muller-Pebody B, Rooney G, Henderson KL, Robotham JV, et al.
707 Association between use of different antibiotics and trimethoprim resistance: going beyond the
708 obvious crude association. J Antimicrob Chemother. 2018;73(6):1700-1707
709
- 710 [27] Lishman H, Costelloe C, Hopkins S, Johnson AP, Hope R, Guy R, et al. Exploring the
711 relationship between primary care antibiotic prescribing for urinary tract infections, Escherichia
712 coli bacteraemia incidence and antibiotic resistance: an ecological study. Int J Antimicrob Agents.
713 2018 Aug 23. doi: 10.1016/j.ijantimicag.2018.08.013
714
- 715 [28] Costelloe C , Metcalf C , Lovering A et al. Effects of antibiotic prescribing in primary care on
716 antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ
717 2010;340:c2096

718

719 [29] Bergman M, Huikko S, Huovinen P, Paakkari P, Seppälä H; Finnish Study Group for
720 Antimicrobial Resistance (FiRe Network). Macrolide and azithromycin use are linked to increased
721 macrolide resistance in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother*.
722 2006;50(11):3646-50

723

724 [30] Chang HH, Cohen T, Grad YH, Hanage WP, O'Brien TF, Lipsitch M. Origin and proliferation of
725 multiple-drug resistance in bacterial pathogens. *Microbiol Mol Biol Rev* 2015;79(1):101–16.

726

727 [31] Lehtinen S, Blanquart F, Lipsitch M, Fraser C, The Maela Pneumococcal Collaboration. On the
728 evolutionary ecology of multidrug resistance in bacteria. *BioRxiv* 2019. Accessed on Jan. 19, 2019.
729 Available from: <https://www.biorxiv.org/content/early/2019/01/10/233957>

730

731 [32] Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R. Does antibiotic exposure increase
732 the risk of methicillin-resistant *Staphylococcus aureus* (MRSA) isolation? A systematic review and
733 meta-analysis. *J Antimicrob Chemother*. 2008;61(1):26-38

734

735 [33] Weber SG, Gold HS, Hooper DC, Karchmer A, Carmeli Y. Fluoroquinolones and the risk for
736 methicillin-resistant *Staphylococcus aureus* in hospitalized patients. *Emerg Infect Dis*.
737 2003;9:1415 -22

738

739 [34] Knight GM, Budd EL, Whitney L, Thornley A, Al-Ghusein H, Planche T, et al. Shift in dominant
740 hospital-associated methicillin-resistant *Staphylococcus aureus* (HA-MRSA) clones over time. *J*
741 *Antimicrob Chemother*. 2012;67(10):2514-22.

742

743 [35] Hicks LA, Bartoces MG, Roberts RM, Suda KJ, Hunkler RJ, Taylor TH Jr, et al. US outpatient
744 antibiotic prescribing variation according to geography, patient population, and provider
745 specialty in 2011. Clin Infect Dis. 2015;60(9):1308-16
746

747 [36] Hope EC, Crump RE, Hollingsworth TD, Smieszek T, Robotham JV, Pouwels KB. Identifying
748 English Practices that Are High Antibiotic Prescribers Accounting for Comorbidities and Other
749 Legitimate Medical Reasons for Variation. EClinicalMedicine 2018;6:36-41
750

751 [37] US CDC. Antibiotic Resistance Patient Safety Atlas. Outpatient Antibiotic Prescription Data.
752 Accessed on Jan. 12, 2019. Available from: <https://gis.cdc.gov/grasp/PSA/indexAU.html>
753

754 [38] US CDC Wonder. Multiple Cause of Death, 1999-2017 Request. Accessed on Jan. 5, 2019.
755 Available from: <https://wonder.cdc.gov/mcd-icd10.html>
756

757 [39] EBM DataLab, University of Oxford. OpenPrescribing data. Accessed on Jan. 12, 2019.
758 Available from: <https://openprescribing.net/analyse/>
759

760 [40] Public Health England. AMR Local Indicators. Accessed on Jan. 12, 2019. Available from:
761 <https://fingertips.phe.org.uk/profile/amr-local-indicators/>
762

763 [41] Epstein L, Dantes R, Magill S, Fiore A. Varying Estimates of Sepsis Mortality Using Death
764 Certificates and Administrative Codes — United States, 1999–2014. MMWR Morb Mortal Wkly
765 Rep 2016;65:342–345.
766

- 767 [42] US Centers for Disease Control and Prevention. Bridged-Race Population Estimates, 1990-
768 2017 data request. Accessed on Jan. 11, 2019. Available from: [https://wonder.cdc.gov/Bridged-](https://wonder.cdc.gov/Bridged-Race-v2017.HTML)
769 [Race-v2017.HTML](https://wonder.cdc.gov/Bridged-Race-v2017.HTML)
770
- 771 [43] United States Census Bureau. MEDIAN HOUSEHOLD INCOME (IN 2011 INFLATION-
772 ADJUSTED DOLLARS) - United States -- States; and Puerto Rico: Households. 2011 American
773 Community Survey 1-Year Estimates (2011). Accessed on Aug. 1, 2018. Available from:
774 <https://factfinder.census.gov/faces/tableservices/jsf/pages/productview.xhtml?src=bkmk>
775
- 776 [44] US CDC Wonder. North America Land Data Assimilation System (NLDAS) Daily Air
777 Temperatures and Heat Index (1979-2011) Request. Accessed on Dec. 1, 2018. Available from:
778 <https://wonder.cdc.gov/nasa-nldas.html>
779
- 780 [45] US Census Bureau. Current Population Survey (CPS) (2018). CPS Table Creator. (Accessed on
781 Nov. 1, 2018). Available from: <https://www.census.gov/cps/data/cpstablecreator.html>
782
- 783 [46] National Health Service (NHS). STAR-PU weightings. Accessed on Jan. 12, 2019. Available
784 from: <https://www.nhs.uk/Scorecard/Pages/IndicatorFacts.aspx?MetricId=443>
785
- 786 [47] Wang HE, Devereaux RS, Yealy DM, Safford MM, Howard G. National variation in United
787 States sepsis mortality: a descriptive study. *Int J Health Geogr.* 2010;9:9
788
- 789 [48] MacFadden DR, McGough SF, Fisman D, Santillana M, Brownstein JS. Antibiotic resistance
790 increases with local temperature. *Nature Climate Change.* 2018;8: 510–514
791

- 792 [49] King A, Mullish BH, Williams HRT, Aylin P. Comparative epidemiology of Clostridium difficile
793 infection: England and the USA. Int J Qual Health Care. 2017;29(6):785-791
794
- 795 [50] Dingle KE, Didelot X, Quan TP, Eyre DW, Stoesser N, Golubchik T, et al. Effects of control
796 interventions on Clostridium difficile infection in England: an observational study. Lancet Infect
797 Dis. 2017;17(4):411-421
798
- 799 [51] Guh AY, Mu Y, Baggs J, Winston LG, Bamberg W, Lyons C, et al. Trends in incidence of long-
800 term-care facility onset Clostridium difficile infections in 10 US geographic locations during 2011-
801 2015. Am J Infect Control. 2018 pii: S0196-6553(17)31295-6.
802
- 803 [52] Morrill HJ, Morton JB, Caffrey AR, Jiang L, Dosa D, Mermel LA, et al. Antimicrobial Resistance
804 of Escherichia coli Urinary Isolates in the Veterans Affairs Health Care System. Antimicrob Agents
805 Chemother. 2017;61(5) pii: e02236-16
806
- 807 [53] Barnato AE, Alexander SL, Linde-Zwirble WT, Angus DC. Racial variation in the incidence,
808 care, and outcomes of severe sepsis: analysis of population, patient, and hospital characteristics.
809 Am J Respir Crit Care Med. 2008;177:279-284
810
- 811 [54] Cheng MP, René P, Cheng AP, Lee TC. Back to the Future: Penicillin-Susceptible
812 Staphylococcus aureus. Am J Med. 2016;129(12):1331-1333
813
- 814 [55] Bidell MR, Palchak M, Mohr J, Lodise TP. Fluoroquinolone and Third-Generation-
815 Cephalosporin Resistance among Hospitalized Patients with Urinary Tract Infections Due to

816 *Escherichia coli*: Do Rates Vary by Hospital Characteristics and Geographic Region? *Antimicrob*
817 *Agents Chemother.* 2016;60(5):3170-3
818
819 [56] Park, SH. Third-generation cephalosporin resistance in gram-negative bacteria in the
820 community: a growing public health concern. *Korean J Intern Med.* 2014;29(1):27-30
821
822 [57] Suresh Babu K, Kastelik J, Morjaria JB. Role of long term antibiotics in chronic respiratory
823 diseases. *Respir Med.* 2013;107(6):800-15.
824
825 [58] Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious
826 Diseases Society of America/American Thoracic Society consensus guidelines on the management
827 of community-acquired pneumonia in adults. *Clin Infect Dis.* 2007;44 Suppl 2:S27-72
828
829 [59] Niederman MS. Macrolide-Resistant *Pneumococcus* in Community-acquired Pneumonia. Is
830 There Still a Role for Macrolide Therapy? *Am J Respir Crit Care Med.* 2015;191(11):1216-7
831
832 [60] US Food and Drug Administration. FDA updates warnings for fluoroquinolone antibiotics.
833 July 2016. Accessed on Jan. 11, 2019. Available from:
834 <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513183.htm>
835
836 [61] Ong P, Gambatese M, Begier E, Zimmerman R, Soto A, Madsen A. Effect of cause-of-death
837 training on agreement between hospital discharge diagnoses and cause of death reported,
838 inpatient hospital deaths, New York City, 2008-2010. *Prev Chronic Dis.* 2015 Jan 15;12:E04